Logo image of SCNX

SCIENTURE HOLDINGS INC (SCNX) Stock Fundamental Analysis

USA - NASDAQ:SCNX - US80880X1046 - Common Stock

0.7162 USD
-0.01 (-1.76%)
Last: 10/15/2025, 8:00:25 PM
0.7299 USD
+0.01 (+1.91%)
After Hours: 10/15/2025, 8:00:25 PM
Fundamental Rating

1

SCNX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. SCNX has a bad profitability rating. Also its financial health evaluation is rather negative. SCNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCNX had negative earnings in the past year.
In the past year SCNX has reported a negative cash flow from operations.
SCNX had negative earnings in 4 of the past 5 years.
SCNX had a negative operating cash flow in each of the past 5 years.
SCNX Yearly Net Income VS EBIT VS OCF VS FCFSCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.30%, SCNX is in line with its industry, outperforming 45.71% of the companies in the same industry.
SCNX has a Return On Equity (-25.86%) which is in line with its industry peers.
Industry RankSector Rank
ROA -19.3%
ROE -25.86%
ROIC N/A
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
SCNX Yearly ROA, ROE, ROICSCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

With a Gross Margin value of 5.77%, SCNX is not doing good in the industry: 88.57% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of SCNX has declined.
The Profit Margin and Operating Margin are not available for SCNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
SCNX Yearly Profit, Operating, Gross MarginsSCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

SCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCNX has more shares outstanding
Compared to 5 years ago, SCNX has more shares outstanding
SCNX has a better debt/assets ratio than last year.
SCNX Yearly Shares OutstandingSCNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
SCNX Yearly Total Debt VS Total AssetsSCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -0.90, we must say that SCNX is in the distress zone and has some risk of bankruptcy.
SCNX has a Altman-Z score of -0.90. This is in the lower half of the industry: SCNX underperforms 60.00% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that SCNX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.03, SCNX is in line with its industry, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -0.9
ROIC/WACCN/A
WACC10.08%
SCNX Yearly LT Debt VS Equity VS FCFSCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.11 indicates that SCNX may have some problems paying its short term obligations.
SCNX's Current ratio of 0.11 is on the low side compared to the rest of the industry. SCNX is outperformed by 97.14% of its industry peers.
A Quick Ratio of 0.11 indicates that SCNX may have some problems paying its short term obligations.
The Quick ratio of SCNX (0.11) is worse than 97.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
SCNX Yearly Current Assets VS Current LiabilitesSCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

SCNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.26%.
The Revenue for SCNX has decreased by -97.10% in the past year. This is quite bad
The Revenue for SCNX have been decreasing by -55.05% on average. This is quite bad
EPS 1Y (TTM)-25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNX Yearly Revenue VS EstimatesSCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
SCNX Yearly EPS VS EstimatesSCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCNX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCNX Price Earnings VS Forward Price EarningsSCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNX Per share dataSCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SCNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCIENTURE HOLDINGS INC

NASDAQ:SCNX (10/15/2025, 8:00:25 PM)

After market: 0.7299 +0.01 (+1.91%)

0.7162

-0.01 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-04 2025-11-04
Inst Owners1.56%
Inst Owner Change0%
Ins Owners11.91%
Ins Owner ChangeN/A
Market Cap15.13M
Analysts82.86
Price TargetN/A
Short Float %1.38%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend3.08
Dividend Growth(5Y)N/A
DP-10.87%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 117.95
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.87
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.01
BVpS3.68
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.3%
ROE -25.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.77%
FCFM N/A
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.48%
Cap/Sales 9.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -0.9
F-Score2
WACC10.08%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5015.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26676.4%
OCF growth 3YN/A
OCF growth 5YN/A